Clinuvel Pharmaceuticals Limited

CUV

AU000000CUV3

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:14 2024-06-28 EDT			5-day change	1st Jan Change
15.37 ^AUD	+0.85%		-0.13%	-3.94%

06-28	Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary	CI
06-24	Clinuvel Pharmaceuticals Secures Orphan Drug Designation in Europe for Metabolic Disorder Drug	MT

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary

June 27, 2024 at 07:11 pm

Clinuvel Pharmaceuticals Limited advised Mr. Peter Vaughan will be appointed Company Secretary, effective 28 June 2024 until 6 August 2024 when a permanent Company Secretary is expected to start employment, with Mr. Darren Keamy stepping down from the role on28 June 2024.

Latest news about Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary	06-27	CI
Clinuvel Pharmaceuticals Secures Orphan Drug Designation in Europe for Metabolic Disorder Drug	06-23	MT
Clinuvel Pharmaceuticals' Afamelanotide Found Effective in Fair-Skinned Parkinson’s Patients	06-17	MT
CLINUVEL Announces A Novel Clinical Program	06-17	CI
Clinuvel Pharmaceuticals Partners Valentech Pharma to Introduce EPP Drug in Latin America	05-22	MT
Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3%	04-28	MT
Clinuvel Pharmaceuticals Launches Share Buyback Program	03-14	MT
Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16	03-13	MT
Clinuvel Pharmaceuticals Limited announces an Equity Buyback for 1,500,000 shares, representing 2.99% of its issued share capital.	03-13	CI
Clinuvel Pharmaceuticals Limited authorizes a Buyback Plan.	03-13	CI
Clinuvel Reports Positive Results in SCENESSE Study	03-03	MT
Transcript : Clinuvel Pharmaceuticals Limited, H1 2024 Earnings Call, Feb 22, 2024	02-22
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-21	CI
Clinuvel Pharmaceuticals Limited Announces Change to Registered Office	12-06	CI
Clinuvel Doses First Patient in Phase 3 Trial of Vitiligo Treatment	23-10-18	MT
Transcript : Clinuvel Pharmaceuticals Limited - Special Call	23-10-01
Clinuvel Pharmaceuticals Limited Announces Board Changes	23-09-28	CI
Clinuvel Pharmaceuticals Teams Up With Vitiligo Experts to Assess Scenesse	23-09-13	MT
Transcript : Clinuvel Pharmaceuticals Limited, 2023 Earnings Call, Aug 29, 2023	23-08-29
Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023	23-08-28	CI
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-28	CI
Clinuvel Pharmaceuticals Secures Supply Contract for Porphyria Medication with the US Department of Veterans Affairs	23-07-26	MT
Clinuvel Pharmaceuticals Secures Patents for Melanocortins for Treatment of Central Nervous System Disorders	23-07-13	MT
Clinuvel Pharmaceuticals Treats First Patient in Phase Two Stroke Trial	23-03-20	MT
Clinuvel Pharmaceuticals Limited Announces Technical Note - CUV803 Study and AIS	23-03-19	CI

Chart Clinuvel Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Companyâs pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Clinuvel Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.37 AUD

Average target price

26.79 AUD

Spread / Average Target

+74.27%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CLINUVEL PHARMACEUTICALS LIMITED	-3.94%	514M
CSL LIMITED	+2.99%	95.18B
SAMSUNG BIOLOGICS CO.,LTD.	-4.34%	37.55B
UCB	+75.79%	28.2B
BIOMARIN PHARMACEUTICAL INC.	-14.61%	15.63B
INCYTE CORPORATION	-3.46%	13.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.31%	11.5B
ALTEOGEN INC.	+184.77%	10.81B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-54.13%	9.23B
SWEDISH ORPHAN BIOVITRUM AB	+6.22%	9.09B

Biopharmaceuticals